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Abstract
Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPNs) are a group of myeloid neoplasms in which
abnormal activation of the Ras signaling pathway is commonly observed. The PI3K/Akt pathway is a known target of Ras;
however, activation of the PI3K/Akt pathway has been shown to lead to neoplastic transformation of not only myeloid but
also lymphoid cells, suggesting that pathways other than the PI3K/Akt pathway should play a central role in pathogenesis of
Ras-mediated MDS/MPN. The MEK/ERK pathway is another downstream target of Ras, which is involved in regulation of cell
survival and proliferation. However, the role of the MEK/ERK pathway in the pathogenesis of MDS/MPN remains unclear.
Here, we show that introduction of a constitutively activated form of MEK into hematopoietic stem cells (HSCs) causes
hematopoietic neoplasms that are limited to MDS/MPNs, despite the multipotent differentiation potential of HSCs. Active
MEK-mediated MDS/MPNs are lethal, but are not considered a frank leukemia because it cannot be transplanted into naı ¨ve
animals. However, transplantation of MDS/MPNs co-expressing active MEK and an anti-apoptotic molecule, Bcl-2, results in
T-cell acute lymphocytic leukemia (T-ALL), suggesting that longevity of cells may impact transplantability and alter disease
phenotype. Our results clearly demonstrate the proto-oncogenic property of the MEK/ERK pathway in hematopoietic cells,
which manifest in MDS/MPN development.
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Introduction
Hematopoietic cells are divided into two groups: lymphoid and
myeloid lineages [1]. Leukemia is caused by neoplastic transfor-
mation of hematopoietic cells. It is estimated that each year 5.6
and 5.8 out of 100,000 people are diagnosed with lymphoid and
myeloid leukemias, respectively [2].
Myeloid neoplasms are sub-divided by the World Health
Organization (WHO) into four sub-groups based on morphology,
immunophenotype, genetics, and clinical features, which include:
acute myeloid leukemia (AML), myelodysplastic syndrome (MDS),
myeloproliferative neoplasm (MPN), and a mixed MDS/MPN
disease [3]. AMLs are marked by genetic abnormalities, such as
chromosomal translocation, and increased blast counts in the
peripheral blood or bone marrow. On the other hand, MDSs are
generally viewed as pre-leukemic conditions that feature ineffective
hematopoiesis that leads to cytopenia(s) [4]. MPNs are a
heterogenous collection of diseases that includes leukemic and
pre-leukemic conditions marked by increased proliferation of
myeloid cells and effective maturation of neoplastic cells [5].
Lastly, the mixed MDS/MPN category, which was added in 2001,
was specifically created to accommodate diseases such as juvenile
myelomonocytic leukemia (JMML) and chronic myelomonocytic
leukemia (CMML) [6]. This modification in the classification
scheme was necessary since these diseases did not belong solely in
the MDS or MPN category because many cases had both
dysplastic and proliferative features [4,6].
MDS/MPNs are a product of inappropriate activation or
inactivation of molecules induced by genetic mutations [7,8]. As a
result, signaling pathways that are normally involved in growth
factor receptor signaling are constitutively activated [8,9]. For
example, activation of Ras, a membrane proximal signaling
molecule and proto-oncogene is frequently observed in various
types of malignant cells generated by neoplastic transformation. In
fact, mutations that result in activation of the Ras gene are found in
30% of human cancer cases including leukemia [10,11]. Moreover,
clinical findings also show that Ras mutations are observed in 20–
60% of CMML cases and 20–25% of JMML cases [8].
However, the role of Ras in transformation events is unclear
because it is located upstream of several pathways, including
MEK/ERK, PI3K/Akt, and Ral-GEF [12]. Various mouse
models have been generated to further dissect each downstream
pathway in order to determine its contribution to malignant
transformation of hematopoietic cells. For example, mouse models
that feature expression of oncogenic K-Ras, either conferred by a
point mutation or ablation of negative regulators such as NF1,
result in MPNs that closely resemble human JMML
[13,14,15,16,17].
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mutations that result in constitutive activation of Akt or ablation of
PTEN, a negative regulator of Akt [18,19]. Regardless of the
mode of activation, neoplasms that result from activation of the
PI3K/Akt pathway begin as pre-leukemic myeloid diseases, but
rapidly convert to a lymphoid disease [20,21,22,23]. For example,
only 10% of mice that expressed activated Akt in the bone marrow
developed AML, while 65% developed an MDS that quickly
progressed to T lymphoma [20]. In mice where PTEN expression
was ablated, 74% of mice developed T-acute lymphoblastic
leukemia (T-ALL) while 26% developed a mixed AML/T-ALL
phenotype [21,22,23]. On the other hand, activation of K-Ras
primarily results in a myeloid disease. The heterogeneity in disease
phenotype and latency strongly suggest that PI3K/Akt signaling
may not be the sole mediator of oncogenic K-Ras signaling and
other downstream pathways such as the MEK/ERK pathway
may be involved.
MEK/ERK are dual serine/threonine specific kinases that are
part of the classical mitogen-activated protein kinase pathway
(MAP kinase) [24]. Of the five MAP kinase pathways, the MEK/
ERK pathway is predominantly activated by a variety of
extracellular stimuli including growth factors, serum, cytokines,
and osmotic stress. This pathway is critically involved in regulating
a variety of cellular processes, such as cell growth, migration,
proliferation, differentiation, and survival [9,24].
Although activating MEK/ERK mutations have not been
identified in any human samples or cancer cell lines, there is
evidence suggesting a link between MEK/ERK and malignant
transformation [25]. A constitutively activated form of MEK1
(active MEK hereafter) was generated by deleting a 20 amino acid
stretch in the N-terminus that regulates kinase activity and
substituting one of the Raf1-dependent regulatory phosphorylation
sites (serine 222) with aspartic acid (DN3-S222D). Introduction of
active MEK resulted in the malignant transformation of NIH3T3
cells [26]. Furthermore, expression of active MEK/ERK is
sufficient to relieve growth factor dependency in hematopoietic cell
lines [27]. Therefore, activation of the MEK/ERK pathway may
play a primary role in malignant transformation of hematopoietic
cells, although this issue has not been directly investigated.
In this study, we found that expression of active MEK alone
resulted in the development of MDS/MPNs but not other types of
hematopoietic malignancies from HSCs. Generation of MDS/
MPNs from HSCs expressing active MEK was not affected by
enhanced cell survival ability, which was conferred by ectopic
expression of Bcl-2, an anti-apoptotic protein. MDS/MPNs
induced by expression of active MEK were not transplantable in
the presence or absence of ectopic Bcl-2. However, T-ALL with
fatal blast crisis was observed in mice transplanted with MDS/
MPN cells positive for active MEK and Bcl-2 after a long latency
period. These results suggest that expression of active MEK is
sufficient for development of myeloid malignancies from HSCs.
Moreover, enhanced cell survival of MDS/MPNs could be
necessary for the development of blast crisis, which mirrors a
similar clinical course observed in human MDS/MPNs. There-
fore, we concluded that the MEK/ERK pathway could play a
significant role in neoplastic transformation of hematopoietic cells.
Results
HSCs expressing active MEK preferentially give rise to
mature granulocyte/macrophage (GM) cells in vivo,
leading to myeloproliferative disorder
To examine whether activation of the MEK/ERK pathway is
sufficient to induce malignant transformation of blood cells, we
purified c-Kit
+Lin
2Sca-1
+ (KLS) cells, which are highly enriched
for HSCs, from wild type (WT) C57Bl/Ka mice. Using a retroviral
transduction system, we introduced active MEK into HSCs and
injected them into sublethally irradiated RAG-2
2/2 mice. The
MSCV retroviral vector employed in our model contains an
IRES-GFP cassette [28]. Therefore, cells productively infected
with retrovirus are positive for GFP expression. Approximately 8
weeks after injection, the mice transplanted with active MEK
+
HSCs became lethargic, had a hunched back appearance, and
experienced weight loss. Moreover, all mice died by 10 weeks post-
injection compared to control mice, which remained healthy and
free of disease for at least 100 days post-injection (Figure 1A).
We examined mice injected with active MEK
+ HSCs at the
terminal stage as well as mice injected with control virus-infected
(GFP
+) HSCs for comparison. Grossly, splenomegaly of active
MEK
+ mice was obvious (Figure 1B). The cellularity of the spleen
was also significantly increased in active MEK
+ mice compared to
control mice (Figure 1C). The marked increase of spleen cells in
the presence of active MEK was specifically due to the expansion
of Mac-1
+ myeloid cells at the expense of T and B lymphocyte
development (Figure 1D). In addition, the structure of the spleen
was disorganized in active MEK
+ mice (data not shown).
Infiltration of cells in the liver and lung of active MEK
+ mice
was also observed (data not shown).
I nt h eb o n em a r r o w ,a v e ra g ec h i m e r is mju d g e db yG F Pe x p r e s si o n
derived from vector control and active MEK mice at the terminal
stage was 6.1% and 56%, respectively, suggesting that cells expressing
active MEK have more proliferative potential in vivo (Figure 1E, left
panels). The population of cells that was most prevalent in mice with
active MEK was the Gr-1
+Mac-1
+ cell population (Figure 1E, center
panels), which contains mature myeloid cells.
To distinguish which population was responsible for the
expansion of myeloid cells and subsequent MDS/MPN, we
purified both c-Kit
+Sca-1
2 myeloid progenitors and Gr-1
+Mac-1
+
mature myeloid cell populations from moribund active MEK or
vector control mice and subjected them to cell cycle analysis.
Committed progenitor populations, such as the common myeloid
progenitor (CMP), have enhanced cell cycle compared to mature
myeloid cells, which are quiescient (Figure S1) [29]. Data obtained
from the mature Gr-1
+Mac-1
+ population in vector control mice
(Figure 1E, right panel) was in good agreement with previously
published results showing that only a fraction of mature myeloid
cells are cycling [29]. However, active MEK mice displayed a
marked increase in the percentage of Gr-1
+Mac-1
+ cells in the G2/
M phase compared to vector control mice (20.2% vs. 11.3%)
(Figure 1E, right panels). These data suggest that MEK signaling
may specifically affect cell cycle status of mature GM cells rather
than more immature myeloid progenitors in the bone marrow. In
addition, neither self-renewal potential nor cell longevity of HSCs
was influenced by active MEK (Figures S2 and S3). Therefore, it
seems that the increase in the number of myeloid cells is due to
enhanced proliferation potential of mature GM cells rather than
the cells at the progenitor and HSC stage in active MEK
+ mice.
Next, we performed differential cell counting of the peripheral
blood from active MEK
+ mice at the terminal stage and control
mice and found that red blood cell and platelet numbers in active
MEK
+ mice were significantly reduced while a slight increase in
leukocytes was observed (Figure 2). We further examined the
peripheral blood from the reconstituted mice at different time
points following injection of active MEK
+ and control HSCs. We
ended this analysis at 6 weeks post-injection because the mice
started to die after this time point. We found that the percentage of
GFP
+ cells in active MEK mice was comparable to vector control
mice until week five, when GFP
+ cells in active MEK mice
Myeloid Disorder by MEK/ERK Activation in Mouse
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28350Figure 1. Expression of Active MEK in HSCs led to the development of MPN. (A) A Kaplan-Meier curve illustrating the survival time of mice
reconstituted with hematopoietic stem cells (HSCs) infected with control (closed circles, n=7) or active MEK (open circles, n=13) retrovirus.
Approximately 7,000 retrovirally infected (GFP
+) HSCs were injected into sublethally irradiated RAG-2
2/2 recipients. Survival of transplanted mice was
monitored for at least 100 days post-injection. (B) Splenomegaly is observed in active MEK mice. (C) Absolute splenocyte counts were determined for
mice injected with HSCs transduced with control (filled circle) or active MEK (open circle) retrovirus at the terminal stage. The horizontal bar denotes
the mean value for each group of mice. *, P,0.05 (statistical significance) by Student t test. (D) Contribution of MEK
+ HSCs to different hematopoietic
lineages. Bone marrow cells were harvested from transplanted mice at the terminal stage for FACS analysis of the various lineage-specific cell surface
markers (B: B220
+ B cells, T: Thy
+ T cells, M: Mac-1
+ myeloid cells). The bar graph summarizes the mean percentage of GFP
+ donor-derived cells for
each cell type for control mice (black bar) and active MEK mice (white bar). Error bars represent the standard deviation from at least 6 mice. *, P,0.05
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of Mac-1
+ cells (Figures 3A and 3B). Reduction in the number of
red blood cells was observed starting at 5 weeks post-injectioin and
became significant at week 6 (Figure 3C). Although other studies
have suggested that activation of the MEK/ERK pathway may
have a negative impact on erythroid differentiation [30,31], our
data suggest that active MEK expression in HSCs does not directly
suppress red blood cell production since mice do not develop
anemia until later time points (Figure 3C). These results
demonstrate that the cause of death of active MEK
+ mice might
be anemia, which appears to be an indirect consequence of the
massive expansion of GM cells, and is a common end-stage
phenotype observed in myeloid neoplasms.
Dysfunctional hematopoiesis that results in anemia, thrombocy-
topenia, and decreased lymphocytes as shown above in active
MEK
+ mice at the terminal stage is characteristic of MDS [4,32].
On the other hand, myeloid cells are able to undergo full and
effective maturation. However, the hyperproliferation of mature
myeloid cells is indicative of MPNs [4,32]. MPNs are also marked
by leukocytosis, which was observed to a moderate degree in our
model (Figure 2). Splenomegly and hepatomegly, two other
common signs of MPNs, were also observed in our mice. Taken
together, these data suggest that expression of active MEK in HSCs
resulted in a mixed MDS/MPN disease, which resembles human
JMML and CMML [4,32]. Therefore, we denote active MEK-
induced myeloid disorder reported here as MDS/MPN hereafter.
MDS/MPN includes various classes of myeloid malignancies,
some of which are classified as pre-leukemic [7,33]. A hallmark of
leukemia is the ability to recapitulate disease in a naı ¨ve animal
following transplantation [34]. To determine the transplantability
of the disease, we harvested unfractionated bone marrow or spleen
cells from individual moribund active MEK
+ mice and injected
them into multiple naı ¨ve, sublethally irradiated RAG-2
2/2 mice.
None of the mice, with the exception of one mouse, developed any
type of malignancy (data not shown). Therefore, active MEK-
induced MDS/MPNs are most likely at the pre-leukemic stage.
Enhanced cell survival alters the course of hematological
malignancies induced by active MEK
Previous reports show that enhanced cell survival conferred by
retroviral introduction of activated Akt into bone marrow cells or
ablation of PTEN expression in mice results primarily in the
development of non-lethal myeloid diseases that progress to a
lethal lymphoid disease [20,21,22,23]. To determine whether cell
survival would alter disease phenotype in our model, we co-
expressed active MEK and Bcl-2, an anti-apoptotic factor. For this
purpose, we used a mouse line that expresses the human Bcl-2
transgene and is driven by the MHC class I promoter. All
hematopoietic cells in this transgenic mouse express Bcl-2 and are
less sensitive to extracellular stimuli that would normally trigger
apoptosis such as X-ray irradiation [35,36].
While all recipient mice injected with Bcl-2/active MEK
+ HSCs
became sick, none of the mice injected with HSCs only expressing
the Bcl-2 transgene became sick (Figure 4A). Mice injected with
Bcl-2/active MEK
+ HSCs reached the terminal stage slightly
earlier than mice injected with WT HSCs expressing active MEK
(average time of death was 56.4 and 66.1 days, respectively)
(Figures 1A and 4A). However, Bcl-2/active MEK
+ mice at the
terminal stage also developed an MDS/MPN very similar to those
observed in active MEK only mice. Our extensive analysis did not
reveal any difference in the disease phenotype observed among
RAG-2
2/2 recipient mice transplanted with active MEK
+ HSCs
in the presence or absence of the Bcl-2 transgene (data not shown).
These results demonstrate that enhanced cell survival does not
alter disease phenotype and has a minimal impact on disease
progression originating from HSCs in the presence of active MEK
expression.
Next, we investigated the transplantability of MDS/MPNs
initiated by active MEK and Bcl-2. As previously mentioned, only
one mouse transplanted with active MEK-induced MDS/MPNs
developed disease (5.9%). In contrast, significantly more mice
transplanted with Bcl-2/active MEK
+-induced MDS/MPNs
became fatally ill (27.8%, p,0.05). Although primary mice died
of MDS/MPNs between 6–10 weeks post-injection of active
MEK
+ or Bcl-2/active MEK
+ HSCs, secondary mice transplanted
with Bcl-2/active MEK
+ MDS/MPNs did not became sick until at
least 15 weeks post-injection (Figure 4A).
We further examined the disease phenotype in the secondary
transplanted mice with MDS/MPNs induced by Bcl-2 and active
MEK at the terminal stage. Different from primary MDS/MPN
mice, we did not observe massive expansion of myeloid cells in the
secondary transplanted mice. Rather, the mice had enlarged thymi
and Thy-1
+ T cells became dominant in the bone marrow, spleen,
Figure 2. Dysfunctional hematopoiesis in terminally ill active MEK mice. Differential cell counting of blood was performed on peripheral
blood harvested from control mice (filled circle, n=6) and active MEK mice (empty circle, n=6). Absolute cell counts were determined using a
HemaVet machine. The horizontal bar denotes the mean value of each group. *, P,0.05 (statistical significance) by Student t test.
doi:10.1371/journal.pone.0028350.g002
(statistical significance) by Student t test. (E) GFP
+ cells in the bone marrow of control (top row, n=4) or active MEK mice at the terminal stage
(bottom row, n=5) were gated and the percentage of mature myeloid cells (Gr-1
+ Mac-1
+) was determined. Gr-1
+ Mac-1
+ cells were sorted and cell
cycle status was examined using intracellular PI staining. The mean percentage of cells in G2/M 6 std dev is indicated.
doi:10.1371/journal.pone.0028350.g001
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of these T cells expressed both CD4 and CD8, suggesting that
expanded T cells in the mouse had an immature T cell phenotype
similar to the CD4
+CD8
+ double positive (DP) population, which
is normally observed in the thymus but not in the periphery
(Figures 4B and 4C). In accordance with their immature
phenotype, T cells from bone marrow and spleen in the secondary
transplanted mice were CD3
2 (Figure 4B). Moreover, peripheral
blood smears obtained from these mice show the presence of blast
cells in the peripheral blood (Figure 4C). Taken together, these
data suggest that the secondary transplanted mice developed T-
ALL.
Notch pathway is exclusively activated in mice with
T-ALL
Greater than 50% of human T-ALL cases have been found to
harbor mutations that result in aberrant activation of the Notch
pathway, which may be necessary for the generation and/or
maintenance of disease [37]. Moreover, certain Notch mutations
have been shown to enhance the malignancy of tumors generated
from introduction of active K-Ras [38].
To determine whether activation of the Notch pathway is
involved in T-ALL generation in the secondary transplanted mice
that received bone marrow or spleen cells harvested from MDS/
MPN mice co-expressing active MEK and Bcl-2, we examined
expression of Notch target genes as performed previously [39]. As
shown in Figure 4D, T-ALL cells expressed significantly higher
levels of the Notch target genes Hes1 and Deltex1 when compared
to phenotypically similar WT DP thymocytes, which only express
basal levels of these genes. Among hematopoietic cells,
CD4
2CD8
2 double negative (DN) thymocytes exhibit high levels
of Notch signaling [40]. However, the level of Notch signaling
observed in our diseased animals exceeds even that found in DN
thymocytes (Figure 4D), which is in agreement with previous
studies showing that the levels of Notch signaling observed in T-
ALLs far exceeds those necessary to mediate physiological
functions [38]. Therefore, activation of the Notch pathway may
be necessary to complete malignant transformation of cells
initiated by active MEK.
Discussion
MEK/ERK transformation potential has been demonstrated in
various cell line systems; however, direct proof in primary
hematopoietic cells was lacking [27,41–43]. In this report, we
provided direct evidence that introduction of active MEK into
HSCs is sufficient to give rise to a MDS/MPN. The MDS/MPN
we observed has features of both CMML and JMML such as lack
of the BCR/ABL fusion gene, persistent peripheral blood
monocytosis, and non-elevated myeloblast or monoblast counts
in the bone marrow and peripheral blood [4,8].
Additionally, our mice also show signs of anemia and
thrombocytopenia, which are characteristic of myeloid dysplasias
observed in CMMLs [4,8]. This myeloid dysplasia was observed
only at later time points, which coincided with an increase in the
percentage of donor-derived GM cells (Figure 3A). These GFP
+
cells were mainly Mac-1
+ (Figure 3B), suggesting that active MEK
signaling does not directly effect erythropoiesis and platelet
production (Figures 2 and 3C). The Gr-1
+Mac-1
+ GM population
of active MEK mice was found to be cycling more than vector
control mice (Figure 1E). Therefore, anemia and thrombocytope-
nia observed at the terminal stage of active MEK mice could be a
consequence of enhanced mature myeloid cell proliferation, which
could out-compete normal cells for space in the bone marrow
resulting in dysfunctional hematopoiesis.
Also, our mice display organomegaly and infiltration of mature
myeloid cells into non-hematopoietic organs, which is more often
Figure 3. In vivo time course analysis of peripheral blood. (A, B)
Peripheral blood was collected from vector control (filled circle, n=3) or
active MEK mice (empty circle, n=5) two weeks post-injection and then
weekly, thereafter. Cells were stained with antibodies and subjected to
FACS analysis. Cells were pre-gated on GFP
+ cells and dead cells were
excluded from the analysis by PI staining. (C) Differential cell counting
was performed on peripheral blood harvested from control mice (filled
circle) and active MEK mice (empty circle) using a HemaVet machine to
assess red blood cell number. Data shown are the mean values from all
mice in each group. Error bars represent the standard deviation from
each group of mice. *, P,0.05 (statistical significance) by Student t test.
doi:10.1371/journal.pone.0028350.g003
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have been linked to activated Ras, the etiology of CMML has been
found to be more heterogeneous, suggesting that dysregulation of
multiple pathways can lead to similar disease phenotypes [8].
The phenotype of active MEK-mediated myeloid disorders
observed in our study is similar to oncogenic K-Ras- but not
PI3K/Akt-mediated myeloid neoplasms [14,15,16,17]. Addition-
ally, inhibition of MEK signaling in oncogenic K-Ras animals
enhances survival and improves myeloid progenitor function [44].
These data suggest that MEK may be the primary mediator of
oncogenic K-Ras signaling. Activation of the PI3K/Akt pathway
appears to favor development of mixed lineage diseases that begin
as MPNs, but rapidly progress to more aggressive diseases, namely
T cell lymphomas and T-ALLs, while only a small percentage
develop AML [20,21,22,23]. Therefore, MEK/ERK and PI3K
share some overlapping functions, but also have distinct roles in
neoplastic transformation of hematopoietic cells.
The PI3K/Akt pathway is primarily associated with cell
survival; however, it is well-known that sole enhancement of cell
survival is not sufficient to cause malignant transformation [45].
For example, translocation events that placed Bcl-2 under the
control of the immunoglobulin heavy chain enhancer coupled with
dysregulated c-Myc expression resulted in lymphoid disease.
However, ectopic expression of Bcl-2 alone is insufficient to
promote oncogenesis [46,47]. These data suggest that dysregula-
tion of the cell cycle and uncontrolled proliferation may be
primary transformation events while prolonged cell survival may
play a supportive role, which allows susceptible pre-leukemic cells
to acquire additional mutations that can lead to blast crisis.
Active MEK-induced MDS/MPN was not transplantable into
naı ¨ve mice, highlighting the pre-leukemic nature of the disease.
These observations led us to ask which cell population was
responsible for the generation of active MEK-induced MDS/
MPN. We investigated self-renewal potential of active MEK
+
HSCs by a serial replating assay on methylcellulose medium and
found that expression of active MEK does not enhance self-
renewal capacity of HSCs (Figure S2). Therefore, it is unlikely that
HSC potential is enhanced by active MEK. Rather, the increase in
Figure 4. Transplantation of Bcl-2/active MEK
+-induced MPNs results in greater frequency of T-ALL. (A) A Kaplan-Meier curve illustrating
the survival time of primary transplanted mice reconstituted with hematopoietic stem cells (HSCs) harvested from a Bcl-2
+ transgenic mouse infected
with control (dotted line, n=8) or active MEK (open circles, n=17) retrovirus and Bcl-2/active MEK
+ secondary transplanted mice (closed circles,
n=18). Approximately 10,000 retrovirally infected (GFP
+) HSCs were injected into sublethally irradiated RAG-2
2/2 recipients for primary transplants.
Survival of primary transplanted mice was monitored for at least 120 days post-injection. Cells from the bone marrow or spleen of mice with Bcl-2/
active MEK
+-induced MDS/MPN were injected into sublethally irradiated naı ¨ve RAG-2
2/2 recipient mice. Survival of secondary transplanted mice was
monitored for at least 365 days post-injection. (B) At the terminal stage, bone marrow was harvested from moribund primary transplanted (top panel)
and moribund secondary transplanted (bottom panel) mice. Secondary transplanted mice were generated by harvesting bone marrow or spleen cells
from moribund active MEK or Bcl-2/active MEK
+ mice and transplanted into naı ¨ve recipient mice. Cells were stained with various lineage antibodies
and subjected to FACS analysis. CD3 expression on Thy-1
+ T cells was further analyzed in primary (dotted arrow) and secondary (solid arrow) mice.
CD4 and CD8 expression in bone marrow was also examined in secondary transplanted mice. All plots are pre-gated on PI
2GFP
+ cells. Data is from
one representative mouse out of five mice. (C) Histology of peripheral blood from secondary transplanted mice. Peripheral blood smears were stained
with Wright-Giemsa stain (top panel). Zoom=4006. Peripheral blood was also subjected to FACS analysis to examine CD4 and CD8 expression. Cells
were pre-gated on PI
2GFP
+ cells. One representative smear and FACS plot is shown for five analyzed mice. (D) Quantitative RT-PCR analysis of deltex-
1 (left panel) and hes-1 (right panel) in CD4
2CD8
2 DN thymocytes (n=3), CD4
+CD8
+ DP thymocytes (n=3), and GFP
+ bone marrow cells from mice
with T-ALL (n=5). Relative expression level for each gene is normalized to b-actin expression level and plotted on a bar graph. The mean normalized
expression level for each group was calculated and used to determine fold induction above DP cells. Expression level of the gene was arbitrarily set at
1 for DP cells. Fold induction over DP is expressed for each corresponding group. Standard deviation was calculated for each sample assayed in
triplicate. *, P,0.05 (statistical significance) by Student t test.
doi:10.1371/journal.pone.0028350.g004
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+Mac-1
+
stage rather than at the progenitor stage (Figures 1E and S1).
Therefore, the numerous progenies that resulted from enhanced
cell cycle status of mature myeloid cells cannot be sustained and
may not be able to generate the same disease in the secondary
transplanted mice. On the other hand, even if transformed
progenitors capable of initiating lymphoid disease were present, we
would not be able to detect them in the primary mice transplanted
with active MEK
+ HSCs because the MDS/MPN was lethal and
had a relatively short latency period (Figure 1A).
While MEK signaling has been shown to be involved in
promoting cell survival, it did not block apoptosis in HSCs
cultured in the absence of growth factor (Figure S3). However,
ectopic expression of Bcl-2 was able to extend this latency period,
which may have allowed multipotent or lymphoid-skewed
progenitors to persist, increasing the likelihood of acquiring
additional mutations. Thus, these conditions may be more
favorable for T-ALL development in Bcl-2/active MEK
+
secondary transplanted mice than secondary transplanted active
MEK only mice. All T-ALLs, regardless of the source of primary
MDS/MPN tumors, were similar. Lymphoblasts in the peripheral
blood and cellular infiltration of multiple organs were observed.
These lymphoblasts expressed both CD4 and CD8 on their cell
surface, but not CD3 (Figures 4B and 4C), which is in good
agreement with their immature morphology.
Further analysis showed that T-ALLs had activated Notch
signaling, whereas MDS/MPNs did not. Our data is in agreement
with models of oncogenic K-Ras where T-ALL development
occurs only after a long latency period and genetic aberrations
such as activating mutations and chromosomal alterations are
observed [16,17,48]. These data suggest that enhanced cell
survival may have contributed to the acquisition of additional
mutations that promote leukemogenesis.
Similarly, active inhibition of apoptosis has been suggested to be
necessary for development of lymphoid neoplasms [49]. Overex-
pression of the oncogene c-Myc in hematopoietic cells resulted in
increased apoptosis and AML development in primary and
secondary transplanted mice. Coupling c-Myc and Bcl-2, an
anti-apoptotic gene that is able to counteract c-Myc-induced
apoptosis, resulted in lymphoid and myeloid diseases in the
primary transplant, but only lymphoid disease in the secondary
transplant [49]. These data suggest that aberrant expression of
oncogenes that promote cell survival may allow lymphoid
leukemia initiators to acquire additional oncogenic ‘‘hits’’. These
newly acquired ‘‘hits’’ can cooperate with existing oncogenes,
which can significantly affect disease progression and phenotype.
MEK/ERK signaling has been implicated in a variety of
cellular functions including proliferation, survival, and differenti-
ation. The results shown in this paper clearly demonstrate that
active MEK can function as an oncogene in hematopoietic cells,
suggesting that MEK/ERK signaling must be tightly regulated in
this cell type. However, we should note that only myeloid disorders
were observed in recipient mice injected with HSCs expressing
active MEK despite the fact that HSCs have multipotent
hematopoietic differentiation potential.
We previously demonstrated that activation of the MEK/ERK
pathway promotes granulocyte/macrophage differentiation from
HSCs both in vivo and in vitro, most likely through its ability to
upregulate C/EBPa, a transcription factor crucial for myeloid cell
development that has also been shown to regulate HSC self-
renewal [50–52]. In addition, ERK can phosphorylate c-Myc, a
well-known cell-cycle regulator, protecting the protein from
proteasomal degradation [53,54]. Reciprocal expression of C/
EBPa and c-Myc has been observed in monocyte cell lines and
they have also been shown to negatively regulate the expression of
each other [55–57]. This suggests that differentiation and
proliferation are mutually exclusive cellular events that do not
occur while the other is in progress. MEK signaling fluctuates as
HSCs commit to the myeloid lineage and differentiate into mature
cells; thus, turning off MEK signaling is important not only to
control cellular proliferation, but also to balance HSC output.
Taken together, our findings provide new insight into the novel
role of the MEK/ERK pathway in leukemogenesis. Our data
suggests that activated MEK can serve as an oncogene in
hematopoietic cells because its activation is sufficient to drive
development of MDS/MPN. Moreover, enforced expression of
Bcl-2 allows transformed cells to acquire additional oncogenic hits,
such as activated Notch signaling. It will be interesting to examine
the interplay between the MEK/ERK and Notch pathways
because both pathways have been shown to be important for
differentiation. Our experimental systems are unique and may be
helpful in future investigations of T-ALL development stemming
from MDS/MPNs.
Materials and Methods
Mice
We used 6–12 weeks of age C57Bl/Ka-Thy1.1-Ly5.2, H2K-
BCL-2 transgenic, and RAG-2
2/2Ly5.2 mice in this study. All
mice were maintained under specific pathogen-free conditions at
the Duke University Animal Care Facility. All procedures were
approved by IACUC at Duke University (permit number, A202-
10-08).
Cytology and complete blood cell counts
Tail vein bleeds were used to collect peripheral blood for weekly
analysis of reconstituted animals. Blood was collected in a
heparinized tube and differential cell counting was done with a
HemaVet 950FS (Drew Scientific Inc.). Peripheral blood was
collected as described and smeared onto glass slides and stained
with Wright-Giemsa stain to examine cytology.
Cell sorting and FACS analysis
For cell surface phenotyping, cells were incubated with normal
rat IgG (Sigma), followed by fluorescence- or biotin-conjugated
antibodies on ice for 20 min. Biotinylated antibodies were further
incubated with fluorochrome-conjugated streptavidin after wash-
ing with staining medium (Hanks’ balanced salt solution (Invitro-
gen, Carlsbad, CA) with 2% fetal calf serum and 0.02% NaN3).
Antibodies used in fluorescence-activated cell sorting (FACS)
and analysis are as follows: phycoerythrin (PE) anti-Thy1.2, PE-
anti-CD8, PE-anti-Sca-1, PE/Cy5 anti-CD3, PE/Cy5 anti-CD4,
PE/Cy5 anti-CD8, PE/Cy5 anti-B220, PE/Cy5 anti-CD19, PE/
Cy5 anti-Gr-1, PE/Cy5 anti-Mac-1, PE/Cy5 anti-Ter119, PE/
Cy5 anti-Thy1.1, PE/Cy5 anti-Thy1.2, PE/Cy7 anti-Gr-1,
allophycocyanin (APC)-anti-Mac-1, APC anti-Thy1.2, APC anti-
c-Kit, APC/Cy7 anti-B220, APC/Cy7 anti-Mac-1, APC/Cy7
anti-CD4, biotinylated CD3. All of the above were purchased
from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or
R&D (Minneapolis, MN). Alexa Fluor 594-anti-Sca-1 was
prepared in our laboratory with a standard procedure. Biotin-
conjugated antibodies were visualized with PE/Cy7-steptavidin
(eBioscience).
FACS sorting and analysis were done on a FACSVantage with
DiVa option equipped with a 488 nm argon laser, a 599 nm dye
laser, and a 408 nm krypton laser (BD Biosciences Flow
Cytometry Systems), which is available in the FACS facility at
the Duke University Comprehensive Cancer Center. Data were
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cells that stained positively by propidium iodide were excluded
from analyses and sorting.
Retroviral production and gene transfer
Active MEK cDNA was cloned into the MSCV-IRES-GFP
vector. We produced virus using 293T cells, which were
maintained in Dulbecco modified Eagle medium (DMEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS as
described elsewhere [28]. Briefly, 293T cells were transfected
with viral constructs along with gag-pol and VSV-G constructs.
Viral supernatants were collected for 4 days and concentrated by
ultracentrifugation at 5610
4g for 4 hrs at 4uC. Virus was aliquoted
and stored at 280uC until use.
Retroviral bone marrow transplantation assay
To purify HSCs (Lin
2Sca-1
+c-kit
+), we harvested bone marrow
cells from tibia and femurs from C57Bl/Ka-Thy1.1-Ly5.2 or
H2K-BCL-2 transgenic mice at 6–12 weeks of age. Bones were
flushed with ice-cold staining medium (Hanks’ balanced salt
solution containing 2% FBS and 0.02% NaN3) to create a single-
cell suspension. Cells were kept on ice for the duration of the
procedure, unless noted. Cells were pelleted by centrifugation at
1,500 rpm for 5 min at 4uC. Cells were then treated with ACK
lysis buffer for 1 min at 25uC to lyse red blood cells and washed
with staining media.
Next, c-Kit
+ cells were enriched by staining whole bone marrow
with anti-CD117/c-Kit microbeads (Miltenyi Biotec, Auburn, CA)
and isolating positively labeled cells using the POSSEL_S mode
with autoMACS cell separation. Cells were then incubated with
rat IgG to block non-specific antibody binding. Cells were then
stained with anti-Sca-1, anti-c-Kit, anti-Lineage (CD3, CD4,
CD8, B220, Gr-1, Mac-1, Ter119) antibodies for 20 min at 4uC.
HSCs were sorted and cultured at 37uC overnight in X-Vivo 15
(BioWhittaker, Walkersville, MD) supplemented with 10% FBS,
stem cell factor (SCF) (50 ng/mL, R&D Systems, Minneapolis,
MN), thrombopoietin (10 ng/mL, R&D Systems, Minneapolis,
MN), and IL-11 (10 ng/mL, R&D Systems, Minneapolis, MN).
Active MEK or control retroviral supernatant was added to the
cells the following day and cells were spun at 2,000 rpm at 25uC
for 2 hrs. Cells were further cultured at 37uC for 24 hrs to allow
for gene expression. Cells were harvested and GFP
+ cells were
sorted, washed with ice-cold staining medium, and resuspended in
RPMI1640 (Invitrogen, Carlsbad, CA) with 10% FBS. HSCs
(1610
4) were injected into the tail vein of sublethally irradiated
(400 rad) RAG-2
2/2 Ly5.2 mice. Eleven active MEK and 7
control mice were analyzed. Also, 13 Bcl-2/active MEK
+ and 10
control mice were analyzed. Following transplantation, recipient
mice were maintained on antibiotic water (sulphamethoxazole and
trimethorpim) and evaluated routinely for signs of morbidity,
weight loss, hunchback appearance, and splenomegaly. Pre-
morbid animals were sacrificed and tissues were harvested and
analyzed by flow cytometry and histopathology.
For secondary transplantations, unfractionated bone marrow
and spleen cells from individual primary transplanted mice were
harvested, washed, and immediately injected into the tail vein of
sublethally irradiated (400 rad) RAG-2
2/2 Ly5.2 mice. Approx-
imately 5610
5–1610
6 bone marrow or 5610
6–10610
6 spleno-
cytes harvested from individual primary transplanted mice were
injected into multiple recipient mice. Eighteen mice were analyzed
for both the active MEK and Bcl-2/active MEK
+ secondary
transplant groups. Following transplantation, recipient mice were
maintained on antibiotic water and evaluated routinely for signs of
disease as described above.
Cell cycle analysis
Cell populations were isolated and sorted based on specific
markers described in the text as previously described. Cells were
washed with staining media, pelleted, and the supernatant was
removed. Next, ice-cold 70% ethanol was added drop-wise to the
sample while vortexing vigorously. Samples were stored in the
dark at 4uC for a minimum of 16 hrs and up to 48 hrs. Cells were
pelleted and the ethanol was carefully aspirated from the top. Cells
were resuspended in 200 mL of PI buffer (16PBS with 0.1%
glucose containing PI and RNase A) and read on a flow cytometer.
Gene expression analysis of bone marrow cells
RNA purification and first-strand DNA synthesis were done as
previously described [39]. Briefly, cells were lysed using 1 ml of
TRIzol reagent (Invitrogen). Total RNA was purified based on the
manufacturer’s instructions. First-strand cDNA was synthesized
with Superscript III RT and random hexamers (Invitrogen).
Quantitative PCR was performed in triplicate on MyIQ (Bio-rad).
The expression level of the gene of interest was calculated and
normalized to Rpl-3 or b-actin. PCR primers are listed below
b-actin-F: 59-GGGAATGGGTCAGAAGGAT-39
b-actin-R: 59-GGGGTGTTGAAGGTCTCAAA-39
Deltex1-F: 59-CAGCCGCCTGGGAAGATGGAGTT-39
Deltex-1-R: 59-TGGATGCCTGTGGGGATGTCATAGAC-39
Hes-1-F: 59-AAAGCCTATCATGGAGAAGACGCG-39
Hes-1-R: 59-GGAATGCCGGGAGCTATCTTTCTT-39
Methylcellulose culture systems
HSCs were sorted and transduced with retrovirus as described
above. After 48 hrs of infection, cells were harvested, stained with
KLS antibodies as previously described, and GFP
+ HSCs cells
were sorted. Sorted cells were washed with staining media, cells
were resuspended to a concentration of 500 cells/10 mLo f
IMDM/well, and 500 mL of MethoCult 3534 (StemCell Tech-
nologies)/well was added directly to the cells. Tubes were capped
and vortexed vigorously. Cells were incubated at 25uC for 20–
30 min and then plated in a 24-well plate using a syringe and 18
K gauge needle. Samples were plated in quadruplicate. Colonies
were enumerated 5–8 days after plating.
Secondary platings were carried out after enumeration. Cells
were harvested, washed twice with PBS, and counted. Cells were
resuspended to a concentration of 5610
4 cells/10 mL IMDM/well,
and 500 mL of MethoCult 3534/well was added directly to the cells.
Cells were processed as previously described. Samples were plated
in quadruplicate. Colonies were enumerated 5–8 days after plating.
Detection of apoptotic cells
HSCs were sorted and infected with retrovirus as previously
described. Following retroviral transduction, cells were harvested
and GFP
+ HSCs were sorted directly into IMDM (Invitrogen,
Carlsbad, CA) with 1% BSA. Cells were pelleted, resuspended in
IMDM with 1% BSA, and plated. Cells were harvested 6 or 12 hrs
later and assayed for apoptosis. Cells were washed with Annexin V
binding buffer (BioLegend, San Diego, CA), incubated with
Annexin V (BioLegend, San Diego, CA) and 7-AAD antibodies
(Invitrogen, Carlsbad, CA) for 15 min on ice, washed twice with
Annexin V binding buffer, and analyzed using a flow cytometer.
Supporting Information
Figure S1 Cell Cycle analysis of myeloid progenitors.
DNA content of myeloid progenitors (Lin
2 c-kit
+) with or without
active MEK was assessed by intracellular PI staining.
(TIF)
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enhance self-renewal. (A–C) HSCs were transduced with
retrovirus expressing vector control (black bars) or active MEK
(white bars). Following transduction, GFP
+ cells were sorted, 500
cells/well were plated on methylcellulose media, and colonies were
enumerated 5–8 days later. The total colony number is shown in
(A). Shape of the representative colony is shown in (B). The
avarage number of colony forming cells is shown in (C). (D) The
total number of colonies in the secondary culture of colony
forming cells in (A–C). NS, P.0.05 (statistical significance) by
Student t test.
(TIF)
Figure S3 Active MEK does not enhance cell survival in
HSCs. Active MEK
+ and control HSCs were cultured in IMDM
with 1%BSA at 37uC for 12 hrs, harvested, washed, stained with
AnnexinV and 7-AAD, and read on a flow cytometer. Results
shown are representative of three independent experiments.
(TIF)
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